UpToDate
UpToDate خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده: 4

Emetogenic potential of single oral antineoplastic agents*

Emetogenic potential of single oral antineoplastic agents*
High/moderate
  • Abemaciclib
  • Adagrasib
  • Avapritinib
  • Bosutinib
  • Cabozantinib
  • Ceritinib
  • Crizotinib
  • Cyclophosphamide
  • Enasidenib
  • Fedratinib
  • Hexamethylmelamine
  • Imatinib
  • Lenvatinib
  • Lomustine
  • Midostaurin
  • Mobocertinib
  • Niraparib
  • Olaparib
  • Procarbazine
  • Ribociclib
  • Rucaparib
  • Selinexor
  • Temozolomide
  • Vinorelbine
Low/minimal
  • Acalabrutinib
  • Afatinib
  • Alectinib
  • Alpelisib
  • Apalutamide
  • Asciminib
  • Axitinib
  • Bexarotene
  • Brigatinib
  • Capecitabine
  • Capmatinib
  • Chlorambucil
  • Cobimetinib
  • Dabrafenib
  • Dacomitinib
  • Darolutamide
  • Dasatinib
  • Duvelisib
  • Encorafenib
  • Entrectinib
  • Erdafitinib
  • Erlotinib
  • Estramustine
  • Etoposide
  • Everolimus
  • Fludarabine
  • Futibatinib
  • Gefitinib
  • Gilteritinib
  • Glasdegib
  • Hydroxyurea
  • Ibrutinib
  • Idelalisib
  • Infigratinib
  • Ivosidenib
  • Ixazomib
  • Lapatinib
  • Larotrectinib
  • Lenalidomide
  • Lorlatinib
  • Melphalan (L-Phenylalanine mustard)
  • Methotrexate
  • Neratinib
  • Nilotinib
  • Nintedanib
  • Olutasidenib
  • Osimertinib
  • Palbociclib
  • Panobinostat
  • Pazopanib
  • Pemigatinib
  • Pexidartinib
  • Pomalidomide
  • Ponatinib
  • Pralsetinib
  • Regorafenib
  • Relugolix
  • Ripretinib
  • Ruxolitinib
  • Selpercatinib
  • Sonidegib
  • Sorafenib
  • Sotorasib
  • Sunitinib
  • Talazoparib
  • Tazemetostat
  • Tegafur/uracil
  • Tepotinib
  • Thalidomide
  • Tioguanin (6-thioguanine)
  • Tivozanib
  • Topotecan
  • Trametinib
  • Trifluridine/tipiracil
  • Tucatinib
  • Umbralisib
  • Vandetanib
  • Vemurafenib
  • Venetoclax
  • Vismodegib
  • Vorinostat
  • Zanubrutinib

* Classified emetic potential of oral agents based upon a full course of therapy and not a single dose within the first cycle.

¶ Emetic potential appears to be at the high end of the moderate category.
From: Jordan K, Chan A, Gralla RJ, et al. Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents—updated MASCC/ESMO consensus recommendation. Support Care Cancer 2023; 32:53. Copyright © 2023 The Authors. Available at: https://link.springer.com/article/10.1007/s00520-023-08220-5 (Accessed on April 11, 2024). Reproduced under the terms of the Creative Commons Attribution License 4.0.
Graphic 144747 Version 1.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟